DENVER, Nov. 03, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today the Center for Biologics Evaluation
New late-breaking data presented today at ASN Kidney Week 2026 QUELIMMUNE (SCD-PED) treatment group demonstrates statistically significant higher survival in the primary analysis at Day 60, Day 90, and at hospital discharge versus comparator cohort No device-related adverse events (AEs) occurred in
Award recognizes Dr. Chung’s extraordinary career as an internationally known expert in burn critical care, combat casualty care, acute organ failure, and extracorporeal organ support Keynote presentation and award ceremony to occur at Update in Critical Care Nephrology 2026 DENVER, Oct.
Potentially accelerates development, assessment, and review for approval by FDA Sepsis impacts about 1.7 million U.S. adults annually and contributes to nearly one in three in-hospital deaths DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a
DENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, today announced the entry into
DENVER, Oct. 02, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that a late-breaking abstract
New codes streamline hospital billing, enable tracking of clinical outcomes, and expand access to QUELIMMUNE ® (SCD-PED) therapy Universal codes establish a framework to enable billing for future potential SCD indications that require renal replacement therapy DENVER, Oct.
Dr. Chung to deliver an oral presentation highlighting QUELIMMUNE ®, an advanced extracorporeal therapy for critically ill pediatric patients with acute kidney injury (AKI) DENVER, Sept. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare
Prestigious honor recognizes Dr. Humes’ pioneering work in developing the Selective Cytopheretic Device (SCD) therapy, commercialized by SeaStar Medical as QUELIMMUNE ® for critically ill pediatric patients with acute kidney injury (AKI) SeaStar Medical’s SCD development pipeline of indications
DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, Chief Executive
